The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease

被引:72
|
作者
Tufekci, Kemal Ugur [1 ]
Genc, Sermin [1 ]
Genc, Kursad [1 ]
机构
[1] Dokuz Eylul Univ, Hlth Sci Inst, Dept Neurosci, TR-35340 Izmir, Turkey
关键词
NITRIC-OXIDE SYNTHASE; NIGRAL DOPAMINERGIC-NEURONS; BLOOD-BRAIN-BARRIER; LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; SINGLE INTRANIGRAL INJECTION; ENVIRONMENTAL RISK-FACTORS; LPS-INDUCED PRODUCTION; NECROSIS-FACTOR-ALPHA; RAT SUBSTANTIA-NIGRA; REGULATORY T-CELLS;
D O I
10.4061/2011/487450
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra. Although the exact cause of the dopaminergic neurodegeneration remains elusive, recent postmortem and experimental studies have revealed an essential role for neuroinflammation that is initiated and driven by activated microglial and infiltrated peripheral immune cells and their neurotoxic products (such as proinflammatory cytokines, reactive oxygen species, and nitric oxide) in the pathogenesis of PD. A bacterial endotoxin-based experimental model of PD has been established, representing a purely inflammation-driven animal model for the induction of nigrostriatal dopaminergic neurodegeneration. This model, by itself or together with genetic and toxin-based animal models, provides an important tool to delineate the precise mechanisms of neuroinflammation-mediated dopaminergic neuron loss. Here, we review the characteristics of this model and the contribution of neuroinflammatory processes, induced by the in vivo administration of bacterial endotoxin, to neurodegeneration. Furthermore, we summarize the recent experimental therapeutic strategies targeting endotoxin-induced neuroinflammation to elicit neuroprotection in the nigrostriatal dopaminergic system. The potential of the endotoxin-based PD model in the development of an early-stage specific diagnostic biomarker is also emphasized.
引用
收藏
页数:25
相关论文
共 50 条
  • [1] Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease
    Kustrimovic, Natasa
    Marino, Franca
    Cosentino, Marco
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (20) : 3719 - 3753
  • [2] Bee Venom Reduces Neuroinflammation in the MPTP-Induced Model of Parkinson's Disease
    Kim, Jong-In
    Yang, Eun Jin
    Lee, Myeong Soo
    Kim, Yong-Suk
    Huh, Youngbuhm
    Cho, Ik-Hyun
    Kang, Sungkeel
    Koh, Hyung-Kyun
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2011, 121 (04) : 209 - 217
  • [3] Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention
    Tansey, Malu G.
    Goldberg, Matthew S.
    NEUROBIOLOGY OF DISEASE, 2010, 37 (03) : 510 - 518
  • [4] Neuroinflammation in Parkinson's Disease
    Lee, Jae-Kyung
    Tran, Thi
    Tansey, Malu G.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2009, 4 (04) : 419 - 429
  • [5] The role of neuroinflammation on the pathogenesis of Parkinson's disease
    Chung, Young Cheul
    Ko, Hyuk Wan
    Bok, Eugene
    Park, Eun Soo
    Huh, Sue Hee
    Nam, Jin Han
    Jin, Byung Kwan
    BMB REPORTS, 2010, 43 (04) : 225 - 232
  • [6] Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
    Gelders, Geraldine
    Baekelandt, Veerle
    Van der Perren, Anke
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [7] Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson's Disease
    More, Sandeep Vasant
    Kumar, Hemant
    Kim, In Su
    Song, Soo-Yeol
    Choi, Dong-Kug
    MEDIATORS OF INFLAMMATION, 2013, 2013
  • [8] Neuroinflammation in Parkinson's disease and its potential as therapeutic target
    Wang, Qinqin
    Liu, Yingjun
    Zhou, Jiawei
    TRANSLATIONAL NEURODEGENERATION, 2015, 4
  • [9] Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Hirsch, Etienne C.
    Hunot, Stephane
    LANCET NEUROLOGY, 2009, 8 (04) : 382 - 397
  • [10] Cyclooxygenase and Neuroinflammation in Parkinson's Disease Neurodegeneration
    Bartels, Anna L.
    Leenders, Klaus L.
    CURRENT NEUROPHARMACOLOGY, 2010, 8 (01) : 62 - 68